CHABLIS-T IIProspective, Multicenter, Open, End-point Blinded, Stratified Block Randomized, Parallel Positive Controlled Clinical Trial of Tenecteplase in Acute Ischemic Stroke With Large Vessel Occlusion Over Time Window

Tenecteplase

The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)

patients without endovascular therapy obtained >50% reperfusion at 4-6 hours

no symptomatic intracranial hemorrhage at 24-36 hours

patients with endovascular therapy: mTICI score 2b or better at initial angiogram

Imaging efficacy outcome: recanalization rate on CT/magnetic resonance angiography

Imaging efficacy outcome: Infarct volume growth (ml) at 3-5 days on MRI or CT perfusion

Clinical efficacy outcome: NIHSS change

Clinical efficacy outcome: percent of excellent functional outcome (modified Rankin scale 0-1) at 90 days (plus or minus 7 days)

Clinical efficacy outcome: percent of good functional outcome (modified Rankin scale 0-2) at 90 days (plus or minus 7 days)

Clinical efficacy outcome: incident event

Imaging safety outcome: Intracranial hemorrhage of any volume at 24-36 hours

Imaging safety outcome: parenchymal hematoma 2 at 24-36 hours

Imaging safety outcome: Symptomatic intracranial hemorrhage at 24-36 hours

Clinical safety outcome: death within 90 days

Clinical safety outcome: Rate of systemic bleeding

Barthel index

Imaging efficacy outcome: patients without endovascular therapy obtained >50% reperfusion at 4-6 hours

Imaging efficacy outcome: patients with endovascular therapy: mTICI score 2b or better at initial angiogram

Imaging efficacy outcome: recanalization rate on CT/magnetic resonance angiography at 3-5 days

Clinical efficacy outcome: NIHSS change at 7 days

Clinical efficacy outcome: vascular death within 90 days

Clinical efficacy outcome: major neurological improvement at 24-36 hours ( NIHSS reduction ≥8 or return to 0-1)major neurological improvement at 24-36 hours ( NIHSS reduction ≥8 or return to 0-1)